Clinical trials: Brain Metastases From Non-small Cell Lung Cancer (NSCLC), open to volunteers
NSCLC Stage IV, Brain Metastases, Adult
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease…
- Trial name
- NCT06401824
- Testing
- Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 25 people
- Sponsor
- Maastricht University Medical Center
Non-Small-Cell Lung Cancer, Brain Metastases
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
- Trial name
- NCT06476093
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Leptomeningeal Disease, Glioblastoma
ctDNA-Guided Intraventricular Therapy for CNS Malignancies
This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or…
- Conditions
- Leptomeningeal Disease, Glioblastoma, Brain Metastases, Non-Small Cell Lung Cancer
- Trial name
- GUIDE-CNS (NCT07689721)
- Testing
- CSF ctDNA-Guided Clinical Management
- Volunteers
- 77 people
- Sponsor
- Alireza Mansouri
Non-small Cell Lung Cancer Metastatic
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC with baseline intracranial metastases.
- Trial name
- NCT05800223
- Testing
- Almonertinib, SBRT
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Cancer Hospital, China
Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets
his study is a Phase II, multicenter clinical trial evaluating the combination of an antibody-drug conjugate (ADC) called Sacituzumab Tirumotecan (SKB264) and brain radiotherapy for patients with advanced non-small cell lung…
- Conditions
- Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07789444
- Testing
- brain radiotherapy, Sacituzumab Tirumotecan (Sac-TMT)
- Volunteers
- 53 people
- Sponsor
- Xiaorong Dong
NSCLC (Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer
This multi-center, prospective, observational study aim to construct a comprehensive model, integrating common clinical pathological parameters, radiographic features and multi-omics data, for assessing the risk and prognosis of…
- Trial name
- NCT07034365
- Testing
- No intervention
- Volunteers
- 2,000 people
- Sponsor
- Fudan University
Seizures, Primary Motor Cortex
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or…
- Conditions
- Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult
- Trial name
- NCT07130786
- Testing
- Levetiracetam (Keppra)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ayal A. Aizer, MD
Brain Metastases, Adult, Brain Tumor - Metastatic
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation…
- Conditions
- Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT07132190
- Testing
- Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ayal A. Aizer, MD
Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases
The goal of this clinical trial is to learn whether adding stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (SRT), delivered on a linear accelerator (LINAC), to osimertinib improves control of brain…
- Conditions
- Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Activating Mutation
- Trial name
- NCT07911449
- Testing
- Osimertinib, Stereotactic Radiosurgery
- Where
- Vietnam
- Volunteers
- 41 people
- Sponsor
- Cho Ray Hospital
Non-Small Cell Lung Cancer, Melanoma
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs.
- Trial name
- USZ-STRIKE (NCT05522660)
- Testing
- Stereotactic radiosurgery, Immune checkpoint inhibitor
- Where
- 15 sites in Italy, Netherlands and 3 more
- Volunteers
- 180 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer, Brain Metastases
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases from non-small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Brain Metastases, Stereotactic Radiation, Immunotherapy
- Trial name
- NCT06702826
- Testing
- Cadonilimab combined with SRS
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Rongrong Zhou
Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma
Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.
- Conditions
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
- Trial name
- NCT07511933
- Testing
- 86-Gallium PSMA PET/CT
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- The Netherlands Cancer Institute
NSCLC Brain Metastasis
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the…
- Trial name
- NCT06716775
- Testing
- Tumor treating felds (TTF), Best Standard of Care
- Volunteers
- 200 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Non Small Cell Lung Cancer
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
This is a randomized, two-arm, comparative Phase II clinical trial designed to evaluate the difference in intracranial progression-free survival (iPFS) between two treatment strategies, assessed locally.
- Trial name
- NCT07234877
- Testing
- Ivonescimab, Carboplatin, Pemetrexed
- Where
- 26 sites in Austria, France and 6 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leptomeningeal Metastasis, Breast Cancer
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
The purpose of this study is to determine the efficacy of BRain-AVOidant proton craniospinal irradiation (BRAVO pCSI) in adult participants with leptomeningeal metastases from solid tumors.
- Conditions
- Leptomeningeal Metastasis, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- BRAVO-LM (NCT07789912)
- Testing
- Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Lung Cancer, Non Small Cell Lung Cancer
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
This is a Phase II, single-arm, multicenter trial for patients with metastatic non-small cell lung cancer who have brain metastases and no known actionable mutations.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Brain Metastases
- Trial name
- TROPICAL-1 (NCT06822543)
- Testing
- Pembrolizumab, Datopotamab deruxtecan, Carboplatin
- Where
- 13 sites in Brazil
- Volunteers
- 46 people
- Sponsor
- Latin American Cooperative Oncology Group
Brain Metastases, Adult, Non Small Cell Lung Cancer
SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
This study aims to evaluate the efficacy of silibinin in preventing recurrence in the brain after complete resection of a brain metastasis (BM) from non-small-cell lung cancer (NSCLC) or breast cancer (BC).
- Conditions
- Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
- Trial name
- SILMET (NCT05689619)
- Testing
- Silibinin
- Where
- 6 sites in Italy
- Volunteers
- 70 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Brain Metastases, Adult, Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial
This pilot pragmatic trial evaluates the feasibility of avoiding radiation therapy in patients with brain metastases who demonstrate an intracranial response to systemic therapy-including immunotherapy, targeted therapy, and/or…
- Trial name
- ACTION-Brain (NCT06974370)
- Testing
- Active Surveillance
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Vermont Medical Center
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc